THE PRESENT INVENTION RELATES TO THE BIOTECHNOLOGICAL FIELD AND PARTICULARLY TO THE HUMAN HEALTH. MORE PARTICULARLY, THE PRESENT INVENTION RELATES TO A VACCINE COMPOSITION FOR THERAPEUTIC USE IN CANCER PATIENTS. THE VACCINE COMPOSITION OF THE PRESENT INVENTION HAS AS ACTIVE PRINCIPLE A CHEMICAL CONJUGATED BETWEEN THE HUMAN RECOMBINANT EPIDERMAL GROWTH FACTOR (hrEGF) AND THE P64K RECOMBINANT PROTEIN. IN ANOTHER EMBODIMENT, THE PRESENT INVENTION RELATES TO THE CONJUGATION PROCEDURE TO OBTAIN, A CHEMICAL CONJUGATED UNDER CONTROLLED AND REPRODUCIBLE PARAMETERS. IN A PREFERRED EMBODIMENT, THE PRESENT INVENTION RELATES TO THE PROCEDURE FOR PURIFYING THE CHEMICAL CONJUGATED WITH A HIGHER PURITY OF THE THERAPEUTICAL VACCINE COMPOSITION, AND A SURPRISINGLY INCREASED IMMUNOGENIC ACTIVITY, INDUCING A SIGNIFICANT INCREASE OF THE ANTI-EGF ANTIBODY TITERS IN HUMANS. ADDITIONALLY THE PRESENT INVENTION PROVIDES THE METHODOLOGY TO OBTAIN A VACCINE COMPOSITION IN SEVERAL DOSE PRESENTATIONS (TOTAL MILLIGRAMS OF CONJUGATED EGF-P64K/VIAL). THE VERSATILITY OF THE DOSE PRESENTATION ALLOWS INCREASING THE IMMUNIZATION DOSE PER PATIENT, WITHOUT INCREASING THE FREQUENCY OF INJECTIONS AND / OR IMMUNIZATION SITES. BESIDES, THE PRESENT INVENTION RELATES TO A SANITARY PROCEDURE FOR OBTAINING A VACCINE COMPOSITION FOR PARENTERAL ROUTE IN THE CANCER THERAP.
